Can Aging Be Treated Like a Disease? | Longevity News Roundup — Week 14, 2026

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED______________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor. Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.______________________News & References:PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/ Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/ Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/ Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/ Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/ Private clinics face longevity learning curve → https://longevity.technology/news/private-clinics-face-longevity-learning-curve/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠